FUNDAMENTALS · Fundamentals · TW Healthcare

Grape King Bio (1707) Fundamentals 2026 — P/E 11.3x, Revenue Analysis | SniperIQ

Grape King Bio (1707) is a TW-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of NT

3.4B, trading at NT$90.60 on the TAI. This SniperIQ fundamentals page covers Grape King Bio's valuation (P/E 11.3x, P/B 2.2x), profitability (net margin 11.5%), revenue (NT
0.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
3.4B
P/E (TTM)11.3x
Net Margin11.5%
Revenue (FY25)NT
0.3B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Grape King Bio's market cap?

Grape King Bio (1707) has a market capitalization of approximately NT

3.4B, trading at NT$90.60 on the TAI. Market cap moves with the live share price.

What is Grape King Bio's P/E ratio?

Grape King Bio's trailing twelve-month P/E ratio is 11.3x, with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Grape King Bio?

Grape King Bio runs a net profit margin of 11.5%, a gross margin of 74.3%, and an operating margin of 20.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Grape King Bio generate?

Grape King Bio reported revenue of NT

0.3B for fiscal year 2025, with net income of NT
.2B and earnings per share (EPS) of 8.22. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Grape King Bio pay a dividend?

Grape King Bio offers a trailing dividend yield of about 6.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Grape King Bio financially healthy?

Grape King Bio carries a debt-to-equity ratio of 0.02x and a current ratio of 1.60x, with a market beta of 0.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Grape King Bio a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Grape King Bio (1707) the key facts are: market cap NT

3.4B, P/E 11.3x, revenue NT
0.3B, 52-week range 90-138. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Grape King Bio's full fundamentals live

Get Grape King Bio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Mabwell (Shanghai) Bioscience (688062) fundamentals · Zhejiang Jiuzhou Pharmaceutical (603456) fundamentals · Solventum (SOLV) fundamentals · Excelsior Medical (4104) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons